Clinical Trials Logo

Recurrent Rectal Adenocarcinoma clinical trials

View clinical trials related to Recurrent Rectal Adenocarcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04109924 Active, not recruiting - Clinical trials for Stage IVA Colorectal Cancer AJCC v8

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Start date: December 27, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating patients with pre-treated colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with bevacizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving TAS-102, irinotecan, and bevacizumab may work better in treating patients with colorectal cancer compared to traditional chemotherapy and bevacizumab.

NCT ID: NCT02874885 Active, not recruiting - Clinical trials for Stage III Rectal Cancer AJCC v8

Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer

Start date: September 5, 2013
Phase:
Study type: Observational

This study looks at the level of circulating tumor elements (cancer cells or DNA pieces floating in the blood) and how it may be related to how the tumor responds to standard treatment in patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Researchers will also compare the level and genetic characteristics of circulating tumor elements between individuals with rectal cancer and healthy individuals to understand how they may change over time. Information from this study may help researchers better understand rectal cancer.